Warnex Inc. (TSX: WNX) announced today the launch of a quantitative test for Campylobacter for use with the real-time PCR-based Warnex(TM) Rapid Pathogen Detection System. With no enrichment required, this test detects and quantifies Campylobacter in poultry rinses within 3 hours. This is the first PCR-based test available to the food industry that quantifies the amount of Campylobacter present in a sample.


"Given the prevalence of Campylobacter infections from food, particularly poultry, there is an increasing need for rapid tests that detect this pathogen," said Mark Busgang, President and CEO of Warnex. "For instance, in Europe, new regulations for decreasing the incidence of Campylobacter infection are imminent. Our test, which detects and quantifies this pathogen, can be instrumental in assisting food companies in improving the safety of their products."


According to the Centers for Disease Control and Prevention (CDC), Campylobacter is one of the most common bacterial causes of diarrheal illness in the United States, with an estimated 2.4 million cases every year. In addition to diarrhea, Campylobacter infections cause cramping, abdominal pain, and fever, and may occasionally cause a serious life-threatening infection for persons with weakened immune systems. Warnex's Campylobacter test detects and quantifies three species of this pathogen, Campylobacter jejuni, C. coli and C. lari, which account for 99% of reported Campylobacter illness cases.


"This achievement of being first to market with a quantitative Campylobacter test underscores the strength of our technology and expertise," said Dr. Yvan Côté, Vice President, Research & Development. "This test is the first in our strategy to produce a series of real-time PCR quantification tests."


Warnex's quantitative Campylobacter test will be commercially available in April 2006.


Warnex also announced today that three more of its tests have been granted "Laboratory Procedure" status by Health Canada, following independent validations by the Canadian Food Inspection Agency (CFIA). These tests include one for E. coli O157:H7 and two semi-quantitative tests for generic E. coli and Staphylococcus aureus. These semi-quantitative tests not only detect the presence of the bacteria, but also indicate whether they are present beyond a user-defined threshold. The test procedures can be found in Volume 3 of the Health Canada Compendium of Analytical Methods, or at http://www.hc-sc.gc.ca/fn-an/res-rech/analy-meth/microbio/volume3/index_e.html


About Warnex


Warnex (www.warnex.ca) is a biotechnology company devoted to protecting public health by providing advanced diagnostic products and science-based services to the agri-food, pharmaceutical and healthcare sectors. Warnex's genomics-based technology offers a versatile detection platform that produces accurate results rapidly, using Real-Time PCR technology combined with unique genetic markers and software. With a focus on pathogen detection in food, our development pipeline also includes applications in GMO testing, meat speciation, as well as in the detection of viruses, yeasts and moulds. Warnex's analytical, bioanalytical, and clinical service groups offer a variety of quality control services, method development and validation, contract R&D, bioavailability and bioequivalence studies for clinical trials, and medical laboratory testing.


Warnex is a trademark of Warnex Inc.


CAUTION REGARDING FORWARD-LOOKING STATEMENTS


Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to the early commercialization of Warnex products, intellectual property and licensing, R&D of new Warnex products, manufacturing and laboratory facilities, suppliers, key employees, key customers, financial resources and credit risk, government regulations, foreign currency risk and volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in the Management's Discussion and Analysis for the third quarter ended on September 30, 2005, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.


%SEDAR: 00010099EF


For further information: please contact: Mark J. Busgang, President & CEO, Warnex Inc., Tel: (450) 663-6724 x.310, mbusgang@warnex.ca; Mike Polonsky, Investor Relations, The Equicom Group Inc., Tel: (416) 815-0700 x.231, mpolonsky@equicomgroup.com